Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
|
|
BBC (10.27.09) - Wednesday, October 28, 2009
A University of Manchester team surveyed 553 girls ages 12-13 from two primary care trusts that offered the three-dose series of Cervarix, GlaxoSmithKline's HPV vaccine. Among those who received the shots, 79 percent "agreed with a statement that vaccination reminded them of the risks of sexual contact," the study found. However, 14 percent said "they might take more sexual risks because they had been vaccinated," it noted.
Among the girls, 77 percent said they participated in their family's decision regarding whether they should get the shots. Ten percent who received Cervarix did not want the shots, while 42 percent of girls whose parents refused the vaccine actually wanted it. A full 93 percent said receiving the vaccine demonstrated how serious they are about their health. One in five found the shot embarrassing because it prevents an STD.
"The vaccine was perceived to be painful, and there were exaggerated rumors of serious adverse events and needle scares," according to the Glaxo-funded study, which was conducted before Britain's national HPV vaccine program rollout.
"The HPV vaccine is an important step towards preventing cervical cancer in the UK, but it will only be truly successful if uptake is high," said Dr. Leslie Walker, director of cancer information at Cancer Research UK. "Despite the scare stories, this research suggests that the HPV vaccine could make the majority of girls more cautious about sex."
About 70 percent of girls ages 12-13 in England were given all three HPV shots during the vaccine program's first year.
The full report, "A Survey of Adolescent Experiences of Human Papillomavirus Vaccination in the Manchester Study," was published online ahead of the printed British Journal of Cancer (2009;doi:10.1038/sj.bcj.6605362).
091028
AD091849
Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.